FDA Announces Draft Guidance On Patient Preference Studies for Drug Development
February 06, 2026
February 06, 2026
WASHINGTON, Feb. 6 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced the availability of a draft guidance for industry regarding the use of patient preference studies (PPS) in the drug development and approval process. Entitled "E22 General Considerations for Patient Preference Studies," the document provides principles for how these studies should be designed, conducted and analyzed to inform regulatory decisions.
The draft . . .
The draft . . .